RECOMBINANT ERITROPOETIN''S INFLUENCE AT CHILDREN WITH SOLID TUMOR ON TRANFUSION ACTIVITY
Effect of use of a recombinant human eritropoetin at children with oncological diseases in a reduction of replacement haemocomponent therapy is defined. Recombinant eritropoetin in treatment of anemia and thrombocytopenia applied at 35 children from 70 surveyed receiving chemotherapy with various cancer. Numbers of recipients and volume of transfusion of an erythrocytes and platelets at treatment of anemia at children are shown advantage use of an eritropoetin in the form of essential reduction of number of transfusions. It is defined that treatment eritropoetiny effectively reduces the total amount of the poured transfusion environments in both studied groups on an erythrocytes and platelets - more than by 4 times. High efficiency of a preparation at children and good tolerance is shown.